EMEA-000480-PIP01-08-M14

Key facts

Invented name
Brilique
Active substance
Ticagrelor
Therapeutic area
  • Cardiovascular diseases
  • Haematology-Hemostaseology
Decision number
P/0175/2021
PIP number
EMEA-000480-PIP01-08-M14
Pharmaceutical form(s)
  • Film-coated tablet
  • Orodispersible tablet
  • Tablet
Condition(s) / indication(s)
Prevention of thromboembolic events
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB

Tel. +46 8553 27591
E-mail: paediatrics@astrazeneca.com

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000480-PIP01-08-M14
Compliance opinion date
25/06/2021
Compliance outcome
positive

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating